Comparison of the Prognostic Utility of the Revised International Prognostic Scoring System and the French Prognostic Scoring System in Azacitidine-Treated Patients with Myelodysplastic Syndromes

Lignende værker

• Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia but does not add to prognostic utility of the revised IPSS
  af: Zeidan, Amer M, et al.
  Udgivet: (2014)
• Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS)
  af: Zeidan, Amer M., et al.
  Udgivet: (2013)
• Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
  af: Prebet, Thomas, et al.
  Udgivet: (2014)
• Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
  af: Prebet, Thomas, et al.
  Udgivet: (2015)
• Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system
  af: Prebet, Thomas, et al.
  Udgivet: (2016)